As a leading Nintedanib Ethanesulfonate Salt supplier, we deliver high-quality products across diverse grades to meet evolving needs, empowering global customers with safe, efficient, and compliant chemical solutions.
What are the indications of Nintedanib Ethanesulfonate Salt?
The indication of Nintedanib + Ethanesulfonate + Salt is related to various symptoms of pulmonary diseases. It is of great use in the treatment of idiopathic pulmonary fibrosis. Idiopathic pulmonary fibrosis is a type of chronic and progressive interstitial lung disease of unknown etiology, in which the lungs gradually fibrosis changes, resulting in impaired respiratory function. Nintedanib ethanesulfonate can delay the progression of this disease and help patients maintain better lung function and quality of life.
Furthermore, in the case of some non-small cell lung cancers, Nintedanib ethanesulfonate may also be suitable. Non-small cell lung cancer is a common type of lung cancer. Nidanib ethanesulfonate can be administered in combination with other anticancer drugs or alone at a specific stage of the disease to control the growth and progression of the tumor, and to seek more vitality and better prognosis for the patient.
In addition, in some rare interstitial lung diseases, clinical research and practice have verified that nidanib ethanesulfonate also has therapeutic effects on some of these diseases, which can relieve the symptoms of patients, improve their lung lesions and overall health. Doctors will accurately determine whether nidanib ethanesulfonate is suitable for the individual according to the patient's specific medical condition, constitution and related examination results, in order to achieve the best therapeutic effect and protect the patient's health.
What are the side effects of Nintedanib Ethanesulfonate Salt?
Nintedanib + Ethanesulfonate + Salt is a medicine used by physicians. Although it has the power to heal diseases, it also has side effects.
bears the brunt of the impact on the gastrointestinal tract. After many patients take this medicine, they often feel nausea, as if there is something surging in the abdomen, and it is difficult to feel comfortable if they want to vomit. What's more, vomiting also occurs from time to time, and the contents of the stomach are poured out, and the body feels weak. And diarrhea is not uncommon, and the stool is thin and the number of times increases, resulting in the body's water grains and essence being difficult to retain, and the righteousness is gradually depleted.
Furthermore, it also affects the function of the liver. Or it can cause abnormal biochemical indicators of the liver, such as elevated transaminase. Liver, the dirty blood storage, the main drain, if the function of the liver is damaged, the flow of qi and blood is abnormal, and various diseases multiply.
Also, this drug may cause changes in the blood system. Platelet count may be abnormal. Platelets are crucial in the process of coagulation. Changes in the number or disorder of the coagulation mechanism can cause skin ecchymosis, petechiae, and severe bleeding of the viscera.
And taking this drug, some patients will also feel tired and weak, slack all over the body, listlessness, and daily labor and activities are affected by it. Because of the effect of the drug, the body's yin, yang, qi and blood are out of balance, and it is difficult to recover righteous qi, so this is the case.
Although nintedanib ethylsulfonate can treat certain diseases, its side effects should not be underestimated. When using drugs, physicians should weigh the advantages and disadvantages and handle them cautiously, so that patients can not only benefit from the drug, but also avoid its harm.
What is the recommended dose of Nintedanib Ethanesulfonate Salt?
What I am asking you is about the recommended dose of "Nintedanib+Ethanesulfonate+Salt". This drug is called nidanib ethanesulfonate, and the recommended dose varies from condition to condition.
In the treatment of idiopathic pulmonary fibrosis, the recommended dose is 150 mg each time, twice a day, with meals. When taking, the whole capsule should be taken with water, not chewed or crushed. The setting of this dose is based on the results of many clinical trials, with the aim of achieving optimal efficacy and keeping side effects within an acceptable range.
In the application of other diseases, such as non-small cell lung cancer, the specific recommended dose may vary depending on the patient's individual condition, combination medication and other factors. Clinicians need to consider the patient's age, physical function, liver and kidney function, and the specific situation of the disease, etc., and carefully determine the appropriate dose. If the patient has doubts about the use of the dose, they should communicate with professional doctors to obtain accurate and safe medication guidance. Do not change the dose at will, so as not to affect the therapeutic effect or cause adverse reactions.
What is the mechanism of action of Nintedanib Ethanesulfonate Salt?
Nintedanib is a small molecule tyrosine kinase inhibitor, and ethanesulfonate salt is its specific salt type. The combination of the two has significant efficacy in the field of medicine. Its mechanism of action is profound and subtle, focusing on the blocking of several key tyrosine kinases.
Tyrosine kinases play a crucial role in cell signaling processes, and many cellular activities such as proliferation, differentiation, and migration are regulated by it. Nintedanib specifically binds to a variety of tyrosine kinases such as platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), and vascular endothelial growth factor receptor (VEGFR).
When Nintedanib binds to these receptors, it can effectively inhibit the autophosphorylation of the receptors, thereby hindering the activation of downstream signaling pathways. It is like cutting off the key chain of cell transmission information, making abnormal cell proliferation and migration signals unable to be transmitted smoothly. Taking pulmonary fibrosis diseases as an example, the excessive proliferation and migration of fibroblasts is a key pathological link. Through the above mechanism of action, Nintedanib can inhibit the abnormal behavior of fibroblasts and slow down the fibrosis process of lung tissue, thus playing a role in alleviating and treating the disease.
In the tumor microenvironment, VEGFR-mediated angiogenesis is of great significance for tumor growth and metastasis. The inhibition of VEGFR by Nintedanib can effectively inhibit tumor angiogenesis, like cutting off the "nutrient supply line" of tumors, making it difficult for tumor cells to obtain sufficient nutrients, thereby inhibiting tumor growth and spread. With such a delicate mechanism of action, this drug has great potential in the treatment of various diseases.
Nintedanib Ethanesulfonate Salt Interacts with Other Drugs
Nitranib ethylsulfonate (Nintedanib+Ethanesulfonate+Salt) may interact with other drugs. This drug is a good drug for the treatment of idiopathic pulmonary fibrosis, but when used in combination with other drugs, it may interact and endanger the disease.
If taken with CYP3A4 strong inhibitors, such as ketoconazole, itraconazole, etc., or cause the blood concentration of nitranib to rise, increasing the risk of adverse reactions, such as hepatotoxicity, gastrointestinal discomfort, etc. The CYP3A4 enzyme is involved in the metabolism of nitranib, and strong inhibitors will hinder this metabolic process.
If used in combination with CYP3A4 strong inducers, such as rifampin, phenytoin sodium, etc., or the blood concentration of nitranib is reduced, its efficacy is reduced. Because it accelerates the metabolism of nintedanib, it is difficult for the drug to reach an effective level in the body.
Other drugs affect the pharmacokinetics of nintedanib, such as proton pump inhibitors (PPIs), or change the pH of the gastrointestinal tract, affecting the absorption of nintedanib. And some anticoagulants, such as warfarin, are used in combination with nintedanib, or increase the risk of bleeding, because nintedanib may affect the clotting function-related pathways.
Therefore, when prescribing nintedanib ethylsulfonate, physicians must consult the patient's medication history in detail, carefully evaluate the interaction with other drugs, and adjust the drug dose or choose alternative drugs according to the specific circumstances of the disease to ensure the safety and efficacy of the drug. If you are sick, you should also follow your doctor's advice. Do not increase or decrease the amount of medication or use other medications on your own. If you have any concerns, communicate with your doctor immediately.